KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to 109.95%.

  • TherapeuticsMD's EBITDA Margin rose 973600.0% to 109.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 61.8%, marking a year-over-year increase of 3108800.0%. This contributed to the annual value of 270.3% for FY2024, which is 5191000.0% up from last year.
  • Per TherapeuticsMD's latest filing, its EBITDA Margin stood at 109.95% for Q3 2025, which was up 973600.0% from 73.0% recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's EBITDA Margin registered a high of 32264.66% during Q2 2022, and its lowest value of 8182.2% during Q3 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 207.31% (2024), whereas its average is 332.13%.
  • As far as peak fluctuations go, TherapeuticsMD's EBITDA Margin surged by 324500900bps in 2022, and later plummeted by -328170600bps in 2023.
  • Over the past 5 years, TherapeuticsMD's EBITDA Margin (Quarter) stood at 230.0% in 2021, then skyrocketed by 149bps to 113.32% in 2022, then tumbled by -255bps to 175.9% in 2023, then surged by 160bps to 104.95% in 2024, then tumbled by -205bps to 109.95% in 2025.
  • Its EBITDA Margin was 109.95% in Q3 2025, compared to 73.0% in Q2 2025 and 221.63% in Q1 2025.